Stephen V Liu, Director of Thoracic Oncology, Head of Developmental Therapeutics and Associate Professor at the Georgetown Lombardi Comprehensive Cancer Center, posted on X:
“More data against concurrent IO and XRT. Phase II study of concurrent pembrolizumab plus chemoradiation for H&N SCC versus sequential CRT followed by pembro. Sequential had superior PFS and fewer immunosuppressive changes on serial biopsy.”
Title: Randomized Phase II Study of Concurrent Versus Sequential Pembrolizumab in Combination With Chemoradiation in Locally Advanced Head and Neck Cancer
Authors: Dan P. Zandberg, Lazar Vujanovic, David A. Clump, Brian P. Isett, Hong Wang, Gabriel Sica, Riyue Bao, Housayin Li, James Ohr, Heath D. Skinner, Raja R. Seethala, Simion I. Chiosea, Robert L. Ferris, Julie E. Bauman
Read the Full Article.
